Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards
Por:
Arribas, L, Sabate-Llobera, A, Domingo, MC, Taberna, M, Sospedra, M, Martin, L, Gonzalez-Tampan, AR, Pallares, N, Mesia, R and Baracos, VE
Publicada:
1 may 2022
Ahead of Print:
1 abr 2022
Resumen:
Background: Computed tomography images acquired during routine cancer care provide an opportunity to determine body composition with accuracy and precision. Quantification of skeletal muscle is of interest owing to its association with clinical outcomes. However, the standards of precision testing considered mandatory in other areas of radiology are lacking from the literature in this area. We aim to describe the change in skeletal muscle over time at different anatomical levels using the precision error.
Methods: Thirty-eight male patients with squamous cell carcinoma of the head and neck were evaluated at two time points encompassing their treatment plan. Precision testing consisted of analyzing the crosssectional area (CSA) of the skeletal muscle and total adipose tissue of 76 CT studies (38 images at baseline repeated twice and 38 follow-up images repeated twice) measured by a skilled observer. The % coeffi-cient of variation (%CV), the root-mean-square standard deviation (RMS SD) and the corresponding 95% least significant change (LSC) were calculated for four anatomical levels: upper arm, thigh, chest and abdomen.
Results: The median time between scans was 223.6 (SD 31.2) days. Precision error (% CV) for total skeletal muscle cross sectional area was 0.86% for upper arm, 0.26% for thigh, 0.39% for chest and 0.63% for abdomen. The corresponding LSC values in upper arm, thigh, chest and abdomen were 2.4%, 0.7%, 1.1% and 1.8%, respectively. Based on the LSC for RMS SD, patients were classified in two categories according to muscle crosssectional area: stable (i.e within LSC value) or gained and loss. To compare the four anatomical levels, the proportion of patients with muscle loss exceeding the LSC value was 74.3% for arm, 86.2% for thigh, 82.9% for chest and 76.3% for abdomen. For these same anatomic regions, the mean muscle loss for those patients classified below the LSC was 14.6% (SD 9.3), 13.4% (SD 7.8), 11.9% (SD 6.5) and 11.6% (SD 5.5), respectively. Only the loss of muscle area was significantly higher in thigh (p = 0.023), using L3 as the reference level.
Conclusions: We recommend the uniform use of a standard precision test when reporting muscle change over time. LSC values vary from 0.7 to 2.4% depending on anatomic site; with the lowest precision error to detect change in the thigh. Based on this analysis, muscle wasting appears to be systemic and while present in limbs and trunk is significantly higher in the thigh than in the chest, abdomen or upper arm. (C) 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Filiaciones:
Arribas, L:
Catalan Inst Oncol ICO, Clin Nutr Unit, Gran Via Hosp 199-203, Barcelona 08908, Spain
Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain
Bellvitge Univ Hosp, Head & Neck Canc Unit, Catalan Inst Oncol ICO, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Sabate-Llobera, A:
Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain
Bellvitge Univ Hosp, PET Unit IDI, Dept Nucl Med, Barcelona, Spain
Domingo, MC:
Bellvitge Univ Hosp, Head & Neck Canc Unit, Catalan Inst Oncol ICO, Barcelona, Spain
IDI Bellvitge Univ Hosp, Dept Neuroradiol, Barcelona, Spain
Taberna, M:
Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain
Bellvitge Univ Hosp, Head & Neck Canc Unit, Catalan Inst Oncol ICO, Barcelona, Spain
ONCOBELL, Med Oncol Dept, Catalan Inst Oncol ICO, Barcelona, Spain
Sospedra, M:
Hosp Univ Germans Trias I Pujol HUGTIP, Unitat Nutr Clin Dietet 1, Barcelona, Spain
Martin, L:
Univ Alberta, Dept Oncol, Div Palliat Care Med, Edmonton, AB, Canada
Gonzalez-Tampan, AR:
Catalan Inst Oncol ICO, Clin Nutr Unit, Gran Via Hosp 199-203, Barcelona 08908, Spain
Bellvitge Univ Hosp, Head & Neck Canc Unit, Catalan Inst Oncol ICO, Barcelona, Spain
Pallares, N:
Bellvitge Univ Hosp, Unitat Bioestadist UBiDi, Barcelona, Spain
:
Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain
Bellvitge Univ Hosp, Head & Neck Canc Unit, Catalan Inst Oncol ICO, Barcelona, Spain
Catalan Inst Oncol ICO Badalona, Med Oncol Dept, B ARGO Grp, Barcelona, Spain
Baracos, VE:
Univ Alberta, Dept Oncol, Div Palliat Care Med, Edmonton, AB, Canada
|